Announcements Trials
Browse Landscape

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 41Observational 4

Sponsor

Cancer Type

Breast 4

Conditions

HER2-positive Breast Cancer 2Breast Neoplasms 2

Interventions

Surveys and Questionnaires 79Blood Specimen Collection 67palbociclib 40Trastuzumab 34Drug Therapy 30Letrozole 29Anastrozole 27Radiotherapy 26Immunohistochemistry 26Mastectomy, Segmental 22Amplified Fragment Length Polymorphism Analysis 22Fulvestrant 21Biopsy 21exemestane 20Tamoxifen 20Interviews as Topic 20Gene Expression Profiling 20Magnetic Resonance Spectroscopy 19ribociclib 18Specimen Handling 18Mastectomy 18Neoadjuvant Therapy 17Paclitaxel 16High-Energy Shock Waves 16Capecitabine 16trastuzumab deruxtecan 15Mammography 15Psychiatric Rehabilitation 14Polymerase Chain Reaction 13Observation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × neratinib × Breast × Clear all
NCT04388384 2025-08-06

ELEANOR

Pierre Fabre Pharma GmbH

Completed
304 enrolled
Breast

Breast Neoplasms

NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT06693024 2024-11-20

NeraHER2

Peking University People's Hospital

Recruiting
2,806 enrolled
Breast

HER2-positive Breast Cancer

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Pierre Fabre Medicament

Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡